CTIS2023-505868-11-00进行中（未招募）1 期
EFFICACY OF COLCHICINE IN SECONDARY PREVENTION OF VASCULAR EVENTS AND RENAL PROGRESSION IN PATIENTS WITH MODERATE CHRONIC RENAL DISEASE (COLCHIREN STUDY). - FIBHGM-ECNC002-2022
Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Maranon0 个研究点目标入组 744 人开始时间: 2023年12月30日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 744
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Age between 18 and 99 years. - Moderate chronic kidney disease, defined as a glomerular filtration rate estimated by the CKD-EPI formula between 30 and 59 mL/min/1.73m2. - History of having suffered a previous cardiovascular event: o Acute coronary syndrome. o Admission for angina pectoris. o Transient ischemic attack or non-cardioembolic ischemic stroke. o Coronary revascularization. o Peripheral vasculopathy, defined as: embolism or acute peripheral arterial ischemia, or need for amputation or percutaneous surgical revascularization. o Finding of coronary artery disease on imaging test. - Legal capacity and voluntary willingness to sign informed consent.
排除标准
- •- History of allergy or intolerance to colchicine or any of its excipients (calcium hydrogen phosphate dihydrate, microcrystalline cellulose, anhydrous colloidal silica, magnesium stearate). - Current treatment with colchicine, or during the month prior to inclusion. - Hospital admission of any cause in the 3 months prior to inclusion in the study. - Active malignant neoplasm (except non-melanoma skin cancer or carcinoma in situ). Patients with a history of malignant neoplasia who have remained free of disease during the previous 3 years can be included. - Uncontrolled or symptomatic chronic inflammatory disease (rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, etc.). - Active infection by hepatitis B virus, hepatitis C virus or human immunodeficiency virus. - Liver cirrhosis of any cause Child-Pugh grade B or C. - Immunosuppressive treatment in the 12 weeks prior to inclusion in the study. - Chronic treatment with non-steroidal anti-inflammatory drugs. - Poorly controlled arterial hypertension (>160/90 mmHg) at the inclusion visit., - Pregnancy and lactation in the inclusion. The use of contraceptive methods is required for women with gestational capacity. Women with gestational capacity are not considered those with: o History of hysterectomy, double salpingectomy, double oophorectomy, or bilateral tubal ligation. o Documented infertility. o Postmenopausal women, defined as amenorrhea for more than 12 months with no other medical cause. In case of doubt, confirmation with elevated follicle stimulating hormone (FSH) levels is recommended. In women with gestational capacity, the use of a contraceptive method of proven effectiveness is required up to 8 weeks after the end of the study. Acceptable methods are as follows: o intrauterine device (IUD) implantation at least 6 weeks prior to study inclusion. o Progestogen-only hormonal contraception associated with ovulation inhibition: oral, injectable, implantable at least 6 weeks prior to study enrollment. o Intrauterine progestin-releasing system at least 6 weeks prior to study enrollment. Combined hormonal contraception (containing estrogens and progestogens) associated with ovulation inhibition : oral, intravaginal , transdermal at least since 6 weeks prior to study inclusion. Other contraceptive methods (sexual abstinence, barrier methods, spermicides, etc.) are not considered acceptable for the study., - Gastric ulcer. - Thrombocytopenia defined as <50000 cells/mcL during the month prior to inclusion. - Neutropenia defined as <1500 cells/mcL during the month prior to inclusion. - Anemia defined as hemoglobin <10.5 g/dL during the month prior to inclusion. - History of aplastic anemia diagnosed by bone marrow biopsy. - Treatment with CYP3A4 and/or P-glycoprotein inhibitors (antivirals, azole antifungals, aminoglycosides, cisclosporin) in the month prior to inclusion in the trial. Treatment with CYP3A4 and/or P-glycoprotein inhibitors (antivirals, azole antifungals, aminoglycosides, cisclosporin) in the month prior to inclusion in the trial.
研究者
相似试验
尚未招募
2 期
Effect of Colchicine on secondary prevention of ischemic strokeIschemic stroke..IRCT20130311012781N5Ahvaz University of Medical Sciences20
已完成
2 期
? The effect of Colchicine in preventing post pericardiotomy syndromepost pericardiotomy syndrome.Pericarditis in diseases classified elsewhereIRCT20141209020258N70Arak University of Medical Sciences120
进行中（未招募）
1 期
ow-dose colchicine for prevention of cardiovascular disease after a cardiovascular eventMedDRA version: 20.0Level: HLGTClassification code 10011082Term: Coronary artery disordersSystem Organ Class: 10007541 - Cardiac disorderscardiovascular diseaseEUCTR2015-005568-40-NLWerkgroep Cardiologische centra Nederland5,447
进行中（未招募）
1 期
Evaluation of the efficacy of colchicine with and without betamethasone mouthwash in the management of recurrent aphthous stomatitis - ART1Recurrent aphthous stomatitis (RAS)EUCTR2006-003327-36-GBGuy's & St Thomas' NHS Foundation Trust136
已完成
不适用
Effects of using Colchicine for the prevention of inflammatory complications, arrhythmias and pain control in the postoperative period of cardiac surgery.PainOther functional disturbances following cardiac surgery.Atrial FibrillationPleural EffusionPericarditisRBR-5f426rxniversidade de Santa Cruz do Sul